These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 9652994

  • 1. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.
    Reginster JY, Meurmans L, Zegels B, Rovati LC, Minne HW, Giacovelli G, Taquet AN, Setnikar I, Collette J, Gosset C.
    Ann Intern Med; 1998 Jul 01; 129(1):1-8. PubMed ID: 9652994
    [Abstract] [Full Text] [Related]

  • 2. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Glüer CC, Mühlenbacher D, Quail D, Schmitt H, Nickelsen T.
    Osteoporos Int; 2003 Sep 01; 14(9):741-9. PubMed ID: 12827224
    [Abstract] [Full Text] [Related]

  • 3. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate.
    Ringe JD, Kipshoven C, Cöster A, Umbach R.
    Osteoporos Int; 1999 Sep 01; 9(2):171-8. PubMed ID: 10367046
    [Abstract] [Full Text] [Related]

  • 4. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy.
    Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom T, Netter P, Loeb G, Rouillon A, Barry S, Evreux JC, Avouac B, Marchandise X.
    Osteoporos Int; 1998 Sep 01; 8(1):4-12. PubMed ID: 9692071
    [Abstract] [Full Text] [Related]

  • 5. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.
    Alexandersen P, Riis BJ, Christiansen C.
    J Clin Endocrinol Metab; 1999 Sep 01; 84(9):3013-20. PubMed ID: 10487657
    [Abstract] [Full Text] [Related]

  • 6. Monofluorophosphate combined with hormone replacement therapy in postmenopausal osteoporosis. An open-label pilot efficacy and safety study.
    Ringe JD, Setnikar I.
    Rheumatol Int; 2002 May 01; 22(1):27-32. PubMed ID: 12120908
    [Abstract] [Full Text] [Related]

  • 7. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, ACTIVE Study Investigators.
    JAMA; 2016 Aug 16; 316(7):722-33. PubMed ID: 27533157
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate.
    Ringe JD, Dorst A, Kipshoven C, Rovati LC, Setnikar I.
    Osteoporos Int; 1998 Aug 16; 8(1):47-52. PubMed ID: 9692077
    [Abstract] [Full Text] [Related]

  • 10. A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures.
    Gutteridge DH, Stewart GO, Prince RL, Price RI, Retallack RW, Dhaliwal SS, Stuckey BG, Drury P, Jones CE, Faulkner DL, Kent GN, Bhagat CI, Nicholson GC, Jamrozik K.
    Osteoporos Int; 2002 Aug 16; 13(2):158-70. PubMed ID: 11908491
    [Abstract] [Full Text] [Related]

  • 11. Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride.
    Delmas PD, Dupuis J, Duboeuf F, Chapuy MC, Meunier PJ.
    J Bone Miner Res; 1990 Mar 16; 5 Suppl 1():S143-7. PubMed ID: 2339624
    [Abstract] [Full Text] [Related]

  • 12. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD.
    JAMA; 1999 Oct 13; 282(14):1344-52. PubMed ID: 10527181
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
    Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB, Treatment of Osteoporosis with Parathyroid Hormone Study Group.
    Ann Intern Med; 2007 Mar 06; 146(5):326-39. PubMed ID: 17339618
    [Abstract] [Full Text] [Related]

  • 17. Fluoride pharmacokinetics and changes in lumbar spine and hip bone mineral density.
    Patel S, Chan JK, Hosking DJ.
    Bone; 1996 Dec 06; 19(6):651-5. PubMed ID: 8968033
    [Abstract] [Full Text] [Related]

  • 18. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ.
    JAMA; 1996 Dec 06; 280(24):2077-82. PubMed ID: 9875874
    [Abstract] [Full Text] [Related]

  • 19. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA, Dussault PM, Thakore-James M, Gagnon D, Baker E, Davis SA, Houranieh AM.
    Epilepsia; 2013 Nov 06; 54(11):1997-2004. PubMed ID: 24010637
    [Abstract] [Full Text] [Related]

  • 20. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M.
    N Engl J Med; 1995 Nov 30; 333(22):1437-43. PubMed ID: 7477143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.